Quantitative susceptibility mapping demonstrates the significance of thalamic pathology in patients with secondary progressive multiple sclerosis: baseline analysis from the MS-STAT2 randomised controlled trial

Authors
Category Primary study
ConferenceMultiple sclerosis journal
Year 2022
This article has no abstract
Epistemonikos ID: e4bb00ec7510457dfed7f1101807a082a8e26693
First added on: Mar 10, 2026